Berbamine inhibits porcine epidemic diarrhea virus in vitro and in vivo

Hongwei Xiang,Jixue Qiao,Haicheng Lin,Jie Li,Yangfan Li,Huihui Sun,Xuan Wang,Ruimin Bi,Zuyao Zhang,Zongyi Bo,Haixiao Shen,Jinchi Zhou,Rui Tong,Xinru Suo,Yuting Xue,Liang Li,Pei Sun

DOI: https://doi.org/10.1016/j.vetmic.2024.110244

2024-08-30

Abstract:Porcine epidemic diarrhea virus (PEDV) is a significant contributor to high mortality rates in piglets, posing a serious threat to the global pig industry. The absence of effective control measures and vaccines against circulating PEDV variants underscores the urgent need for new treatment strategies. In this study, we screened a compound library and identified Berbamine as a potential anti-PEDV drug through molecular docking techniques. In vitro experiments demonstrated that Berbamine significantly inhibits PEDV proliferation in Vero and IPEC-J2 cells in a dose-dependent manner, primarily targeting the replication phase of the PEDV life cycle. Furthermore, in vivo experiments revealed that Berbamine effectively alleviates intestinal damage caused by PEDV infection in piglets, leading to a reduction in viral load and cytokine levels, including IL-6, IL-8, IL-1β, and TNF-α. Additionally, autodock predictions indicate that viral non-structural proteins 3 and 16 (Nsp3 and Nsp16) are potential targets for Berbamine. Consequently, Berbamine holds significant promise for application and development as an antiviral treatment against PEDV.